Literature DB >> 21068649

Influence of CYP2C9 genetic polymorphism and undernourishment on plasma-free phenytoin concentrations in epileptic patients.

Kesavan Ramasamy1, Sunil K Narayan, Deepak Gopal Shewade, Adithan Chandrasekaran.   

Abstract

The objective of this study was to study the effect of CYP2C9 genetic polymorphism and undernourishment on free phenytoin concentrations in epileptic patients. The study was done in 70 patients who were taking phenytoin therapy for the treatment of epileptic seizures. Genotyping of CYP2C9 (*2 and *3) was determined by the polymerase chain reaction-restriction fragment length polymorphism method. Bound and free plasma phenytoin was separated using equilibrium dialysis technique. Total and free phenytoin concentrations were measured by the reverse-phase high-performance liquid chromatography method. Patients were broadly classified into well-nourished and undernourished and further subclassified by CYP2C9 genotypes. In well-nourished groups (G1 to G3 group), free phenytoin concentrations were significantly higher in the heterozygous poor metabolizer of CYP2C9 genotype (G2) group (3.1 ± 0.62 μg/mL) and homozygous poor metabolizer of CYP2C9 genotype (G3) group (4.3 ± 1.76 μg/mL) when compared with patients with the wild-type CYP2C9 (G1) group (1.1 ± 0.72 μg/mL). Similarly, in undernourished patient groups (G4-G6 group), free phenytoin concentrations were significantly higher in the wild-type CYP2C9 (G4) group (2.5 ± 0.52 μg/mL), heterozygous poor metabolizer of CYP2C9 genotype (G5) group (4.3 ± 1.76 μg/mL), and homozygous poor metabolizer of CYP2C9 genotype (G6) group (8.2 ± 1.08 μg/mL) when compared with well-nourished patients with the wild-type CYP2C9 (G1) group (1.1 ± 0.72 μg/mL). The percentage increase in free phenytoin concentration by undernourishment, CYP2C9 allelic variants, and undernourishment cum CYP2C9 allelic variants were 127%, 290%, and 472%, respectively, compared with well-nourished patients with the wild-type CYP2C9 genotype (G1) group. The contribution of undernourishment and genetic factors (CYP2C9 allelic variant) for developing phenytoin toxicity was calculated to have an odds ratio of 37.3 (P < 0.0001). Undernourishment and variant CYP2C9 alleles elevate free phenytoin concentrations individually and in combination show additive effects.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21068649     DOI: 10.1097/FTD.0b013e3181fa97cc

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  9 in total

1.  CYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy.

Authors:  A Ortega-Vázquez; P Dorado; I Fricke-Galindo; H Jung-Cook; N Monroy-Jaramillo; I E Martínez-Juárez; I Familiar-López; E Peñas-Lledó; A LLerena; M López-López
Journal:  Pharmacogenomics J       Date:  2015-06-30       Impact factor: 3.550

2.  PharmGKB summary: very important pharmacogene information for human leukocyte antigen B.

Authors:  Julia M Barbarino; Deanna L Kroetz; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2015-04       Impact factor: 2.089

3.  Genotype-phenotype correlation of cytochrome P450 2C9 polymorphism in Indian National Capital Region.

Authors:  Ekta Varshney; Nilanjan Saha; Monika Tandon; Vikesh Shrivastava; Shakir Ali
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2013-02-28       Impact factor: 2.441

Review 4.  PharmGKB summary: phenytoin pathway.

Authors:  Caroline F Thorn; Michelle Whirl-Carrillo; J Steven Leeder; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2012-06       Impact factor: 2.089

5.  Participation of Monocarboxylate Transporter 8, But Not P-Glycoprotein, in Carrier-Mediated Cerebral Elimination of Phenytoin across the Blood-Brain Barrier.

Authors:  Ryuta Jomura; Shin-Ichi Akanuma; Björn Bauer; Yukiko Yoshida; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2021-02-01       Impact factor: 4.200

6.  Role of CYP2C9, CYP2C19 and EPHX Polymorphism in the Pharmacokinetic of Phenytoin: A Study on Uruguayan Caucasian Subjects.

Authors:  Natalia Guevara; Cecilia Maldonado; Manuel Uría; Raquel González; Manuel Ibarra; Silvana Alvariza; Antonella Carozzi; Carlos Azambuja; Pietro Fagiolino; Marta Vázquez
Journal:  Pharmaceuticals (Basel)       Date:  2017-08-18

7.  CYP2C9 Variations and Their Pharmacogenetic Implications Among Diverse South Asian Populations.

Authors:  Sheikh Nizamuddin; Shivendra Dubey; Sakshi Singh; Saurav Sharma; Pratheusa Machha; Kumarasamy Thangaraj
Journal:  Pharmgenomics Pers Med       Date:  2021-01-27

8.  Clinical pharmacogenomics in action: design, assessment and implementation of a novel pharmacogenetic panel supporting drug selection for diseases of the central nervous system (CNS).

Authors:  E Bothos; E Ntoumou; K Kelaidoni; D Roukas; N Drakoulis; M Papasavva; F A Karakostis; P Moulos; K Karakostis
Journal:  J Transl Med       Date:  2021-04-15       Impact factor: 5.531

Review 9.  Effects of genetic polymorphism of drug-metabolizing enzymes on the plasma concentrations of antiepileptic drugs in Chinese population.

Authors:  Weixuan Zhao; Hongmei Meng
Journal:  Bioengineered       Date:  2022-03       Impact factor: 6.832

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.